The Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Reducing Pathologic Scar Formation After Median Sternotomy.

What Was Tested

Researchers studied Angiotensin II in this observational study publication.

This study aimed to investigate the effects of ACE inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) on pathological scar formation, following median sternotomy, focusing on the role of the renin-angiotensin system (RAS) in tissue remodelling and wound healing.

Scar formation was evaluated using the Patient and Observer Scar Assessment Scale (POSAS v2.0), which assesses both subjective and objective parameters.

Why It Was Studied

Designed as a cross-sectional observational study, it included 100 patients who had undergone median sternotomy at least 6 months prior and were receiving continuous antihypertensive treatment.

Patients were categorised into three groups based on their medications: ACEIs (n = 33), ARBs (n = 35), and other antihypertensives (n = 32).

Who Took Part

The study group was 100 patients.

By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.

What Was Measured

The subject headings attached to it are Cross-Sectional Studies, Angiotensin-Converting Enzyme Inhibitors, Sternotomy, Wound Healing, Cicatrix, Angiotensin Receptor Antagonists and Keloid.

The authors tagged it with the keywords angiotensin II receptor antagonist, angiotensin converting enzyme inhibitors, angiotensin‐renin system and median sternotomy.

What This Means in Plain Language

This is an observational study of Angiotensin II in 100 patients.

The publication is from 2026 (Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society), a journal based in United States.

More context: the Angiotensin II compound page, all human trials.